Skip to main content

Table 3 Association factors of OS and DFS in stage III patients

From: Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study

 

Overall survival

Disease-free survival

Univariable analysis

Multivariable analysis

Univariable analysis

Multivariable analysis

Factors

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

Treatment

 Surgery alone

1 (Reference)

–

1 (Reference)

–

1 (Reference)

–

1 (Reference)

–

 Surgery/adjuvant chemotherapy

0.572 (0.360–0.910)

0.018

0.568 (0.357–0.903)

0.017

0.542 (0.342–0.859)

0.009

0.511 (0.322–0.811)

0.004

Age of diagnosis

 65–70 years

1 (Reference)

–

1 (Reference)

–

1 (Reference)

–

  

  > 70 years

1.560 (1.021–2.385)

0.040

1.573 (1.029–2.405)

0.036

1.409 (0.926–1.943)

0.109

  

Time of surgery

 2004–2014

1 (Reference)

–

  

1 (Reference)

–

1 (Reference)

–

 2015–2018

0.895 (0.565–1.417)

0.636

  

0.630 (0.405–0.980)

0.041

0.586 (0.376–0.912)

0.018

Sex

 Male

1 (Reference)

–

  

1 (Reference)

–

  

 Female

0.987 (0.609–1.602)

0.959

  

0.957 (0.591–1.55)

0.860

  

ECOG score

 0

1 (Reference)

–

  

1 (Reference)

–

  

 1

1.345 (0.848–2.132)

0.207

–

–

1.493 (0.948–2.351)

0.083

  

 2

1.201 (0.576–2.507)

0.625

  

1.335 (0.643–2.773)

0.438

  

 2+

2.810 (1.098–7.188)

0.031

  

2.715 (1.061–6.950)

0.037

  

Charlson score

 0

1 (Reference)

–

  

1 (Reference)

–

  

 1

1.038 (0.609–1.771)

0.890

  

1.119 (0.664–1.885)

0.674

  

 2

1.000 (0.364–2.749)

0.999

  

1.186 (0.477–2.946)

0.713

  

 2+

–

–

      

Tumor location

 Gastroesophageal junction

1 (Reference)

–

  

1 (Reference)

–

  

 Antrum

1.347 (0.838–2.166)

0.219

  

1.368 (0.858–2.183)

0.188

  

 Other

1.862 (0.917–3.780)

0.086

  

1.521 (0.753–3.073)

0.242

  

Retrieved lymph node

1.001 (0.991–1.010)

0.853

  

0.999 (0.989–1.009)

0.782

  

Hospital stays

1.001 (0.980–1.023)

0.905

  

1.005 (0.986–1.025)

0.600

  

T stage

 T1–2

1 (Reference)

–

  

1 (Reference)

–

  

 T3

0.596 (0.130–2.729)

0.505

  

0.464 (0.103–2.098)

0.318

  

 T4

0.722 (0.176–2.958)

0.651

  

0.576 (0.141–2.358)

0.443

  

N stage

 N0

1 (Reference)

–

  

1 (Reference)

–

  

 N1

0.223 (0.040–1.231)

0.085

  

0.234 (0.042–1.288)

0.095

  

 N2

0.517 (0.121–2.207)

0.373

  

0.555 (0.131–2.357)

0.425

  

 N3

1.071 (0.261–4.398)

0.924

  

1.065 (0.259–4.375)

0.930

  

Histologic Grade

 Well or moderately differentiated

1 (Reference)

–

  

1 (Reference)

–

  

 Poorly differentiated or undifferentiated

1.035 (0.609–1.759)

0.899

  

1.043 (0.615–1.769)

0.877

  

Lymphatic, blood vessel or perineural invasion

 Yes

1 (Reference)

–

  

1 (Reference)

–

  

 No

0.899 (0.581–1.389)

0.631

  

0.741 (0.484–1.134)

0.167

  

Tumor size

  ≤ 5 cm

1 (Reference)

–

  

1 (Reference)

–

  

  > 5 cm

1.209 (0.793–1.843)

0.377

  

1.147 (0.756–1.738)

0.519

  
  1. HR hazards ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, AJCC American Joint Cancer Committee
  2. We adjusted for the following variables: treatment regimens (with adjuvant chemotherapy or not), age of diagnosis, time of surgery, sex, ECOG score, Charlson score, tumor location, retrieved lymph node, hospital stays, T stage, N stage, histologic grade, lymphatic, blood vessel or perineural invasion, and tumor size
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us